New hope in the fight against cancer

Thanks to a history of clinical trials research, people with cancer are living longer and with a better quality of life than ever before. Cancer research is advancing at a fast pace and, as a result, researchers are able to develop targeted therapies that are changing the standards of care and saving lives.

Some patients may fear that enrollment in a clinical trial means they may receive no treatment at all. The reality is that patients in studies receive either the best treatment currently known for their specific cancer, or a new, and possibly more effective, therapy. Placebos are never used in place of treatment when an existing therapy exists.

Current oncology treatment trials open for participation:

Breast

1. CALGB 40101 – Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 cycles) vs. Paclitaxel (4 vs. 6 cycles) as adjuvant therapy for breast cancer in women with 0-3 positive axillary lymph nodes: A 2x2 Factorial Phase III Randomized Study
2. IBCSG 24-02 – A Phase III Trial evaluating the role of Ovarian Function Suppression and the role of Exemestane as Adjuvant Therapies for Premenopausal women with Endocrine responsive breast cancer
3. SWOG 0226 – Phase III Randomized Trial of an Anastrozole vs. Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
4. PACCT-1 – Program for the Assessment of Clinical Cancer Tests: Trial Assigning IndividuaLized Options for TReatment" The TAILORx Trial

Gastrointestinal

1. CALGB 80101 – Phase III Intergroup Trial of Adjuvant Chemoradiation after resection of gastric or gastroesophageal Adenocarcinoma
2. ECOG 5202 – A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
3. CALGB 80405 – A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Prostate

1. CALGB 90401 – A Randomized double-blinded placebo controlled Phase III trial comparing Docetaxel and prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer.
2. ECOG 2805 – Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Head and Neck

1. ECOG 1304 – Phase II Two Arm Trial of the Proteasome inhibitor, PS-341(VELCADE) in combination with Irinotecan or PS-341 alone followed by the addition of Irinotecan at time of progression in pt. with locally recurrent or metastatic Squamous Cell Carcinoma of the Head and Neck

Hematology

1. ECOG 4402 – Phase III Trial Comparing Two Different Rituximab Dosing Regimes for Patients with Low Tumor Burden Indolent Non- Hodgkin’s Lymphoma
2. SWOG 0106 – Phase III Study of Addition of Gemtuzumab Ozogamicin (Mylotarg) Induction Therapy vs. Standard Induction with Daunomycin & Ara-C Followed by Consolidation & Subsequent Randomization to Post Consolidation treatment with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for patients under age 56 with previously untreated de novo acute myeloid leukemia (AML).
3. ECOG 1905 – A Randomized Phase II trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the treatment of Myelodysplastic Syndrome, chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia.
   

Lung

1. AVF3671g – A Randomized Double-Blinded, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy with or without Erlotinib after Completion of Chemotherapy with Bevacizumab for the First-line Treatment of Locally Advanced, Recurrent of Metastatic Non-Small Cell Lung Cancer

Melanoma

1. ECOG 1697 – Phase III Randomized Study of Four Weeks High Dose IFN-"2b in Stage T3 - T4 or N1 (microscopic) Melanoma